Results 331 to 340 of about 689,752 (349)

Tumor Stage in Non-Small Cell Carcinoma of the Lung

Chest, 1991
This article is the second in a planned series from the Section on Cancer of the ACCP. The first article (Little AG, Stitik FP: Clinical staging of patients with non-small cell lung cancer. Chest 97:1431-38, 1990) focused on clinical approaches to staging and emphasized the role of: (1) radionuclide scanning; (2) computed tomography; (3) magnetic ...
C.F. Mountain, Greenberg Sd, Armando E. Fraire   +2 more
openaire   +3 more sources

Elastase levels in small and non - small cell lung carcinoma

Biochemical Society Transactions, 1993
Elastase (E.C.3.4.21.37) constitutes the most important component in the proteolytic enzyme spectrum of neutrophilic granulocytes [ I ] . Elastase is the only enzyme which can hydrolyze insoluble elastin 121. In addition, elastase can hydrolyze several other tissue components including connective tissue macromolecules, plasma proteinase inhibitors and ...
Güner, G, Kirkali, G, Karlikaya, C, Akkoçlu, A, Baskin, YASEMİN   +4 more
openaire   +5 more sources

Chromogranin A gene expression in non‐small cell lung carcinomas

The Journal of Pathology, 1998
Evidence for the existence of neuroendocrine (NE) differentiation in non-small cell lung carcinomas (NSCLCs) is at present based on histochemical, ultrastructural, and immunohistochemical data. The aim of this study was to investigate the extent of NE differentiation in NSCLCs as revealed by mRNA analysis.
ABBONA G., PAPOTTI, Mauro Giulio, VIBERTI L., MACRÄ­ L., STELLA A., BUSSOLATI, Giovanni   +5 more
openaire   +4 more sources

Prognostic biomarkers in non-small-cell lung carcinoma [PDF]

Current Diagnostic Pathology, 2006
Summary Lung cancer is the leading cause of cancer death in the world. The vast majority are of the non-small-cell lung carcinoma (NSCLC) histological type, for which the only effective treatment remains surgical resection. However, most of NSCLC are non-resectable at the time of diagnosis and some patients would benefit from adjuvant chemotherapy ...
Elisabeth Brambilla, Sylvie Lantuejoul
openaire   +1 more source

Galectin-3 expression in non-small cell lung carcinoma

Cancer Letters, 2004
Galectins are a family of animal beta-galactoside-binding lectins involved in malignant transformation and progression. The present study evaluated the immunohistochemical expression of galectin-3 in a consecutive series of 81 radically resected non-small cell lung carcinomas (NSCLCs).
PUGLISI, Fabio, MINISINI, Alessandro Marco, BARBONE, Fabio, INTERSIMONE, Donatella, APRILE, Giuseppe, PUPPIN, Cinzia, DAMANTE, Giuseppe, PARON, Igor, TELL, Gianluca, PIGA, Andrea, DI LORETO, Carla   +10 more
openaire   +4 more sources

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Journal of Clinical Oncology, 2003
PURPOSE The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic agents.
F. Hirsch, M. Varella-Garcia, P. Bunn, Michael V. Di Maria, R. Veve, Roy M Bremmes, A. Baron, C. Zeng, W. Franklin   +8 more
semanticscholar   +1 more source

Non-small Cell Lung Carcinoma

2008
Publisher Summary This chapter focuses on the role of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in diagnosing lung cancer. FDG-PET is highly accurate in characterizing pulmonary mass lesions that are either unsuitable for or have failed histopathological characterization, even when they do not fulfill the classical definition of ...
Robert E. Ware, Rodney J. Hicks
openaire   +2 more sources

Chronic oral etoposide in non-small cell lung carcinoma

European Journal of Cancer, 1992
25 consecutive inoperable or extended non-small cell lung cancer (NSCLC) patients (19 non-chemotherapy pretreated, 6 non-heavily pretreated) were given oral etoposide, 50 mg/m2/day for 21 successive days, every 4 weeks. 5 partial responses (PR), 9 disease stabilizations were achieved; the overall response rate of 20% (95% confidence interval, 4% to 36%)
H. Palombo, Jaume Grau, Nuria Viñolas, Albert Biete, Jordi Estapé, Josep Ramírez, Carlos Agustí, J Sanchez-Lloret, C. Solá, M. Daniels   +9 more
openaire   +3 more sources

Molecular Pathogenesis of Non-Small Cell Lung Carcinomas

Journal of Lung Cancer, 2012
Non-small cell lung carcinoma (NSCLC) from histological and biological perspectives is a complex neoplasm. The sequential preneoplastic changes have been defined for centrally arising squamous cell carcinomas (SCCs) of the lung, and they are less documented for peripherally arising adenocarcinomas.
openaire   +2 more sources

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

International Journal of Radiation Oncology, Biology, Physics, 2017
Linda C. Chen, J. Douglass, L. Kleinberg, X. Ye, A. Marciscano, P. Forde, J. Brahmer, E. Lipson, W. Sharfman, H. Hammers, J. Naidoo, C. Bettegowda, M. Lim, K. Redmond   +13 more
semanticscholar   +1 more source